Oculis OCS 深 沪
已收盘 09-25 16:00:00 美东时间
9.27
-0.140
-1.49%
华盛通- 最 高9.71
- 今 开9.71
- 成交量 23.96万股
- 最 低 9.10
- 昨 收 9.41
- 总市值 5.72亿
- 52周最高 34.475
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 9.10
- 委 比 58.47%
- 总股本 6173.21万
- 历史最高 34.475
- 量 比 1.02
- 振 幅 6.48%
- 历史最低 6.26
- 每 手 1
- 风险率 6.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic macular edema. The biotechnology company aims to advance the investigational therapy into clinic...
09-24 23:41
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank cut the price target for Xenon Pharmaceuticals Inc (NASDAQ:XENE) from $90 to $46. Deutsche Bank ...
09-18 20:31
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $26 to $39.
09-18 18:53
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Sept. 17, 2026 -- A notification regarding the purchase of ordinary shares by a member of the Company’s Board of Directors is attached. The document can be accessed via the provided link.
09-17 20:05
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG has initiated the PIONEER-1 trial to evaluate Privosegtor for optic neuritis (ON), with the first patient treated in the U.S. Privosegtor, a novel neuroprotective agent, showed promising results in the Phase 2 ACUITY trial, leading to FDA Breakthrough Therapy and EMA PRIME designations. The trial aims to assess visual recovery and safety, with potential broader applications in neurology, including acute multiple sclerosis relaps...
08-24 08:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $23 to $20.
08-15 00:25
Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.48) by 58.33 percent. This is a 64.91 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $392.150 thousan...
08-07 15:54
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis Holding AG reported Q2 2026 results, highlighting progress in its neuro-ophthalmology pivot with Privosegtor advancing in optic neuritis and potential expansion into acute MS relapses following positive FDA feedback. Licaminlimab's PREDICT-1 trial for dry eye disease is on track with over 45% patient enrollment. The company has $282.3 million in cash, providing runway into H2 2029. Upcoming milestones include R&D Day for Privosegtor and to...
08-06 20:05
